ZTS

Zoetis Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - ZTS

Published: Jul 20, 2026   |  Read Original Article ↗

Article Summary

HOLD
  • Zoetis Inc. (NYSE: ZTS) is being sued for violations of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated by the Securities and Exchange Commission.
  • The lawsuit alleges that Zoetis made false and misleading statements to the market during a period spanning January 14, 2025 to May 6, 2026, as Zoetis faced challenges in multiple product lines including Librela, Apoquel, and Cytopoint.
  • Shareholders who purchased shares during the class period listed are encouraged to contact the DJS Law Group regarding possible lead plaintiff appointments.
Free users see 3 BUY signals per day. Premium unlocks all of them, plus instant email alerts. See Plans
Growth Stock Metric Rating
ZTS Rating
59.0
WEAK HOLD

Growth Stock Scoring Breakdown

METRIC VALUE WEIGHT ANALYSIS
Sales Growth TTM ? 2.4% 25% 20.0 ptsMinimal (2.4%) - Very weak
EPS Growth Next 5Y ? 7.6% 25% 20.0 ptsWeak (7.6%) - Low expectations
Target Price Upside ? 42.2% 20% 95.0 ptsHuge Upside (42.2%) - Target: $108.64 vs Current: $76.40
Gross Margin % ? 70.4% 15% 100.0 ptsExceptional (70.4%) - Strong pricing power
Drawdown from 52-Wk High ? -52.4% 15% 100.0 ptsDeep Discount (-52.4%) - Best entry opportunity
Disclaimer: This rating is for informational purposes only and is not financial advice. All data sourced from Finviz. Always conduct your own research and consult with a financial advisor before making investment decisions. Past performance does not guarantee future results.

ZTS - Daily Chart

Loading chart data...
Powered by Finviz & ApexCharts

About ZTS

Healthcare Drug Manufacturers - Specialty & Generic 14,500 employees Parsippany, NJ, United States
  • Zoetis Inc. engages in the discovery, development, manufacture, and commercialization of medicines, vaccines, diagnostic products and services, biodevices, genetic tests, and precision animal health solutions for the animal health industry in the United States and internationally.
  • The company commercializes products primarily across companion animals comprising dogs, cats, and horses; and species, including livestock, such as cattle, swine, poultry, fish, and sheep.
  • It also offers parasiticides, vaccines, dermatology, anti-infectives, pain and sedation, other pharmaceutical, and animal health diagnostics.
  • In addition, the company provides animal health diagnostics, including point-of-care diagnostic products, instruments and reagents, rapid immunoassay tests, reference laboratory kits and services, and blood glucose monitors; and other non-pharmaceutical products, which include nutritionals, as well as products and services in biodevices, genetic tests, and precision animal health.
  • It markets its products to veterinarians, livestock producers, and pet owners.
  • The company has collaborated with Blacksmith Medicines, Inc. to discover and develop novel antibiotics for animal health.
  • Zoetis Inc. was incorporated in 2012 and is headquartered in Parsippany, New Jersey.
Get BUY-rated growth stocks delivered after market close.